RealFeedApp CEO Rohit Batta describes disease symptoms as an accelerator stuck down
Alethio Therapeutics secured $90 million to advance treatments for myeloproliferative neoplasms, a group of hematological malignancies including primary myelofibrosis and polycythemia vera. CEO Rohit Batta described the condition as a constant drive with no brake, leading to complications like clots and bone marrow scarring.
- Field
- drugs and trials
- What they did
- Alethio Therapeutics received $90 million in funding to develop treatments for rare myeloproliferative neoplasms, including primary myelofibrosis and essential thrombocythemia.
- Why it matters
- Current treatments like frequent blood withdrawals or JAK inhibitors are often insufficient because the disease progresses slowly but constantly, leading to complications such as blood clots and bone marrow scarring.
#alethio#myeloproliferative neoplasms#blood cancer#funding#biotech
